Associate Director of GSK, United States
Driss Oraichi is a seasoned expert in mathematics, statistics, and epidemiology with a robust background in both academic and industry settings. With extensive experience in managing and analyzing large datasets and conducting epidemiological research, Dr. Oraichi is dedicated to advancing public health through rigorous statistical methods and collaborative research. Fluent in English, Arabic, and French, he is committed to mentoring and fostering the next generation of statisticians and researchers.
Education
Driss Oraichi earned his Bachelor’s Degree in Mathematics with a focus on Numerical Analysis from Hassan II University in Casablanca, Morocco, in 1991. He then completed his Master’s in Applied Mathematics at the University of Geneva, Switzerland, in 1997, with a thesis on Algebraic Differential Equations. Dr. Oraichi achieved his Ph.D. in Mathematics, specializing in Statistics, from the University of Quebec in Montreal, Canada, in 2002, with a dissertation on Integer-Valued Nonlinear Time Series Models.
Dr. Oraichi brings over 24 years of expertise in mathematics, statistics, biostatistics, and epidemiology. His career spans academia, the pharmaceutical industry, and consulting organizations. As an Associate Director at GlaxoSmithKline Vaccines in Rockville, USA, he led statistical oversight for vaccine safety and effectiveness studies, collaborated on study design, and contributed to regulatory submissions. Previously, he worked as a Research Associate at CHU Sainte Justine in Montreal, Canada, where he designed and analyzed epidemiological studies and supervised students. Dr. Oraichi also served as a Sessional Lecturer at the University of Quebec in Montreal, teaching mathematics and statistics, and began his career as a high school teacher in Casablanca.
Research focus
Dr. Oraichi’s research focuses on advanced statistical methodologies, including generalized linear models, survival analysis, and time series analysis. His work extensively involves real-world data (RWD) analysis, including insurance claims and electronic health records. He is particularly interested in observational healthcare research, evaluating the safety and effectiveness of drugs and vaccines.
• Marshall JK., Bessette L., Thorne C., Shear NH., Lebovic G., Gerega SK., Millson B.,
Oraichi D., Gaetano T., Gazel S., Latour MG., Laliberté MC. Impact of the Adalimumab
Patient Support Program’s Care Coach Calls on Persistence and Adherence in Canada:
An Observational Retrospective Cohort Study. Clinical Therapeutics 2018 Mar; Volume
40, Issue 3 pages 415-429.
• Santos F., Oraichi D., Bérard A. Prevalence and predictors of anti-infective use during
pregnancy. Pharmacoepidemiology and Drug Safety 2010 Apr;19(4):418-27.
• Gendron MP., Martin B., Oraichi D., Bérard A. Health care providers` requests to
Teratogen Information Services on medication use during pregnancy and lactation.
European Journal of Clinical Pharmacology 2009 May;65(5):523-31.
• Moussally K., Oraichi D., Bérard A. Herbal product use during pregnancy: Prevalence
and predictors. Pharmacoepidemiology and Drug Safety 2009 Jun;18(6):454-61.
• Ramos E., Ofori B., Oraichi D., Bérard A. Antidepressant therapy during pregnancy: an
insight on its potential health care costs. Canadian Society for Clinical Pharmacology,
2008 Fall;15(3).
